

REMARKS

Claims 1, 4-7, and 17 are pending in the subject application. Claims 2, 3, and 8-16 have been cancelled as being drawn to unelected subject matter without prejudice to Applicants' pursuit in any patent application. By this amendment, Applicants have amended claims 1 and 17. Support for the amendments can be found, inter alia, within the specification on pages 38-44. Thus, the changes do not constitute new matter.

Rejection under 35 U.S.C. §112, second paragraph – Claims 1 and 17

The Examiner has rejected claims 1 and 17 under 35 U.S.C. 112, second paragraph, and helpfully suggests language that would be acceptable. In response, Applicants have amended claims 1 and 17 to recite that language. Accordingly, Applicants respectfully submit that the rejection is overcome.

Conclusion

Applicants respectfully request that the claims are in condition for Allowance and request a timely Notice of Allowance be issued in this case. Commissioner is authorized to charge any deficiencies and credit any overpayment to OSI Pharmaceuticals, Inc. Deposit Account No. **502783**.

Attorney for Applicants can be reached at the telephone number and address below.

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

OSI PHARMACEUTICALS, Inc.
By Shu M. Lee Date 19 Feb 2004

February 19, 2004
OSI Pharmaceuticals, Inc.
58 South Service Road, Suite 110
Melville, NY 11747

Respectfully submitted,



Shu M. Lee
Attorney for Applicants
Registration No. 41,147
Telephone No. (631) 962-2056
or (516) 924-4035
Fax No. (631) 752-3880